The global antisense oligonucleotides market size was valued at USD 3.72 billion in 2025 and is projected to grow from USD 3.96 billion in 2026 to USD 6.60 billion by 2034, registering a CAGR of 6.57% during the forecast period (2026-2034). North America dominated the antisense oligonucleotides market with a share of 52.44% in 2025.
The antisense oligonucleotides market (ASOs) includes short, synthetic strands of nucleic acids designed to bind to specific RNA sequences and modify gene expression. Antisense oligonucleotides are commonly classified under HSN Code 3002 (human blood, antisera, vaccines, toxins, and other immunological products, where applicable) and SIC Code 2834 (Pharmaceutical Preparations).
The antisense oligonucleotides market demand is driven by research into genetic disorders and the need for treatments that target disease-causing RNA. Pharmaceutical and biotechnology companies are developing chemically modified antisense oligonucleotides and splice-switching therapies to regulate gene silencing and address specific disease mechanisms.
Download a Free Sample To learn more about this report,
Shift toward Exon Skipping Antisense Oligonucleotide Therapies
The antisense oligonucleotides market analysis shows growth in exon skipping therapies designed to address specific genetic mutations by modifying how genetic instructions are processed. These therapies bind to selected regions of pre messenger RNA and encourage cells to skip a targeted exon during RNA splicing, helping restore the production of a partially functional protein in certain genetic disorders.
Integration of Biomarker-Based Patient Selection in Antisense Treatment
Integration of biomarker based patient selection is shaping the antisense oligonucleotides market by helping researchers identify patients who are more likely to benefit from specific RNA targeting therapies. Genetic testing and molecular biomarkers can help confirm disease related mutations, assess target RNA expression, and guide treatment selection in suitable patient groups.
Supply chain disruptions are expected to have a high impact on the antisense oligonucleotides market share due to dependence on specialized nucleotides, chemical reagents, and synthesis materials, The market is expected to follow a stair-Sstep recovery, as shortages of specialized raw materials and delays in pharmaceutical manufacturing can slow production. The market is expected to grow at a CAGR of 6.57%, but supply chain constraints could lower this by 0.9 percentage points, resulting in a growth of around 5.67%. As supply conditions normalize, the antisense oligonucleotides market growth is expected to gradually return to 6.57%.
The antisense oligonucleotides market forecasts strategic investment activity driven by advancement of ASO therapies into late-stage clinical trials and development of targeted treatments for rare genetic disorders.
Key Investment and Funding Activities in the Antisense Oligonucleotides Market, 2026
AusperBio Therapeutics
USD 120 Million
In August 2026, AusperBio closed a Series C financing round to advance AHB-137, an antisense oligonucleotide (ASO) candidate for chronic hepatitis B, through Phase 3 development and toward potential commercialization.
Oak Hill Bio
USD 32.5 Million
In June 2026, Oak Hill Bio raised Series A funding to advance rugonersen, an investigational ASO therapy for Angelman syndrome, into a pivotal Phase 3 clinical study.
Research into Neurological and Neuromuscular Disorders and Demand for Treatments Targeting Disease-Causing RNA Drives Market
Research into neurological and neuromuscular disorders is supporting the antisense oligonucleotides market as researchers explore treatments for conditions caused by specific genetic changes. Disorders such as spinal muscular atrophy and certain forms of amyotrophic lateral sclerosis have encouraged the development of therapies that target disease-related RNA.
Demand for treatments targeting disease-causing RNA is contributing to the antisense oligonucleotides market because these therapies can influence how specific genetic instructions are processed or expressed. By targeting selected RNA sequences, antisense oligonucleotides may help reduce harmful protein production or modify RNA processing, depending on the disease and treatment design.
Stringent Regulatory Approval Requirements and Risk of Adverse Effects and Toxicity Restrain Market Expansion
Stringent regulatory approval requirements create challenges for the antisense oligonucleotides market because these therapies require detailed evaluations of safety, efficacy, manufacturing quality, and potential long-term effects. The complexity of assessing novel genetic-targeting treatments can increase clinical trial costs and extend development timelines. Antisense oligonucleotide therapies may cause adverse effects such as injection-site reactions, liver or kidney toxicity, and changes in blood platelet levels, depending on the drug and its chemical structure. These risks require careful dose selection, safety monitoring, and long-term patient follow-up. Concerns about treatment tolerability may limit patient acceptance and increase the complexity and cost of clinical development.
Expansion of Antisense Oligonucleotides for Rare Genetic Disorders and Extrahepatic Tissues Offers Growth Opportunities
Biotechnology companies and pharmaceutical developers can target patients with rare genetic disorders caused by specific RNA abnormalities. Antisense oligonucleotides can be designed to modify RNA processing or reduce the production of disease-associated proteins, creating opportunities for targeted treatment development. Revenue can be generated through drug commercialization, licensing agreements, research partnerships, and contributing to antisense oligonucleotides market growth.
Drug developers and biotechnology companies can invest in delivery technologies that help antisense oligonucleotides reach tissues beyond the liver, including muscle, the central nervous system, and other targeted organs. Improved delivery approaches can expand the range of diseases that may be addressed using antisense-based treatments.
Phosphorothioate-modified ASOs accounted for the largest share of 31.5%, owing to their improved resistance to enzymatic degradation and established use in antisense drug development. These chemical modifications help improve oligonucleotide stability and support therapeutic applications targeting disease-related RNA.
The peptide nucleic acid (PNA) ASOs segment is anticipated to record a growth rate of 9.15% during the forecast period, driven by interest in their high binding affinity for complementary nucleic acid drug sequences and resistance to enzymatic degradation.
Request Customizationto receive a tailored report.
Neurological and neuromuscular disorders dominated the therapeutic area segment with a share of 39.5%, reflecting the use of antisense therapies to target disease-associated genetic mechanisms. These treatments can modify RNA processing or reduce the production of specific disease-related proteins.
Autoimmune disorders are estimated to register a growth rate of 8.45% during the forecast period, fueled by research into targeted approaches for regulating genes and molecular pathways involved in immune-mediated diseases.
Pharmaceutical and biotechnology companies led the end user segment, accouting for a share of 48.5% in 2025 This dominance is led by their extensive involvement in antisense drug discovery, clinical development, and commercialization.
CROs and CMOs are projected to experience a growth rate of 8.35% during the forecast period, propelledby the demand for outsourced research, oligonucleotide synthesis, analytical testing, and manufacturing services. These providers help drug developers access specialized expertise and production capabilities throughout antisense therapy development.
Speak to an Analystto discuss market opportunities.
The North America antisense oligonucleotides market accounted for a dominant share of 52.44% in 2025.
U.S. Food and Drug Administration has approved antisense oligonucleotide therapies such as Spinraza for spinal muscular atrophy and Qalsody for amyotrophic lateral sclerosis. These treatments demonstrate the clinical application of antisense technology to modify RNA processing or reduce disease-associated protein production, supporting continued development of targeted RNA therapeutics.
A Phase III clinical trial listed in Health Canada's clinical trial portal is evaluating sefaxersen, an antisense inhibitor of complement factor B, in patients with primary immunoglobulin A (IgA) nephropathy who are at high risk of disease progression. This clinical development highlights the application of gene-silencing technology to targeted treatment and supports research activity in RNA therapeutics.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific antisense oligonucleotides market is estimated to reach 8.46% CAGR during the forecast period, making it the fastest-growing region.
Researchers at India's CSIR–Institute of Genomics and Integrative Biology are developing an antisense oligonucleotide approach targeting the PPP2R2B gene, which is associated with spinocerebellar ataxia type 12 (SCA12). The approach aims to reduce disease-associated RNA production and is currently at the early research stage. This work highlights India's potential to develop gene-silencing treatments for rare genetic disorders and advance precision medicine.
China's clinical development of AHB-137, an investigational antisense oligonucleotide targeting hepatitis B virus RNA, has demonstrated dose-dependent reductions in hepatitis B surface antigen in early-stage studies involving patients with chronic hepatitis B. These findings support further evaluation of antisense-based treatments aimed at achieving functional control of viral infection.
A first in Japanese Phase I study of sefaxersen evaluated an antisense oligonucleotide targeting complement factor B messenger RNA. The study involved 24 healthy Japanese participants and found dose-dependent reductions in markers of the complement alternative pathway, with no new safety signals reported. These findings support the evaluation of antisense therapeutics for IgA nephropathy and other diseases involving abnormal complement activity.
Europe's antisense oligonucleotides market is expected to achieve a growth rate of 6.15% during the forecast period.
Germany's Medicines for Europe and the European Medicines Agency's regulatory framework for advanced therapies supports the development and authorization of innovative treatments for rare genetic diseases. The country's specialized clinical and pharmaceutical infrastructure also enables the translation of molecular biology advances into targeted medicines, including therapies that regulate RNA processing and gene expression.
UK Government's Rare Therapies Launch Pad is developing a pathway to improve access to individualized treatments for people with rare, life-limiting genetic conditions, including personalized antisense oligonucleotide therapies. The pilot is intended to address practical challenges in developing, regulating, and reimbursing treatments designed for individual genetic variants.
Latin America antisense oligonucleotides market will expand to 6.75% CAGR during the forecast period. Brazil's treatment landscape for spinal muscular atrophy includes nusinersen, an antisense oligonucleotide therapy that modifies SMN2 RNA splicing to increase production of functional survival motor neuron protein.
Mexico's clinical management of Duchenne muscular dystrophy highlights the potential need for genetic treatments that address mutations in the DMD gene. Exon-skipping antisense oligonucleotides are designed to skip specific exons during RNA processing, helping restore the reading frame and enable production of a shorter form of dystrophin in eligible patients.
The Middle East & Africa antisense oligonucleotides market is likely to reach at a CAGR of 5.95% during the forecast period. Abu Dhabi launched and funded a clinical trial for gene therapy targeting MerTK-related retinitis pigmentosa, a rare inherited eye disorder.
The initiative strengthens clinical development capabilities for genetic diseases and supports future RNA-targeted drug development. South Africa’s 110,000 Human Genome Programme is developing a national genomic medicine reference database to improve understanding of genetic variation and disease susceptibility.
The antisense oligonucleotides market competitive landscape is highly fragmented, with established biotechnology companies, RNA-targeted therapy developers, and specialized genetic medicine providers. Key players such as Ionis Pharmaceuticals, Sarepta Therapeutics, Biogen, Wave Life Sciences, and Novartis are estimated to account for 35–40% of the global antisense oligonucleotides market share.
Established players compete mainly through RNA-targeting technologies, clinical research, and regulatory approvals. Emerging and regional players in the antisense oligonucleotides market ecosystem focus on chemically modified oligonucleotides and specialized therapies for genetic, neurological, and rare diseases treatments.
September 2026: Ionis Pharmaceuticals announced positive topline results from the Phase III FUSION study of ulefnersen, an investigational antisense oligonucleotide (ASO) therapy for FUS-associated amyotrophic lateral sclerosis (FUS-ALS).
September 2026: Ionis Pharmaceuticals received U.S. FDA approval for ZANVASTRO (zilganersen), an antisense oligonucleotide therapy for Alexander disease in pediatric and adult patients.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cell Harvesting Systems Market Size, Forecast, Demand, Opportunities, 2034
Cell Culture Market Size, Share, Growth, Analysis, Report, 2034
Automated Sample Storage Systems Market Size, Forecast, Opportunities, 2034
Biosensors Market Size, Share, Growth, Analysis, Report, 2034
B Cell Lymphoma Treatment Market Size, Share, Growth, 2034
Apoptosis Testing Market Size, Forecast, Demand, Opportunities, 2034
We are featured on:
sales@straitsresearch.com